Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00605384 | Oral cavity | EOLP | skeletal muscle organ development | 35/2218 | 166/18723 | 4.65e-04 | 4.08e-03 | 35 |
GO:000647521 | Oral cavity | EOLP | internal protein amino acid acetylation | 34/2218 | 160/18723 | 4.79e-04 | 4.19e-03 | 34 |
GO:000918524 | Oral cavity | EOLP | ribonucleoside diphosphate metabolic process | 25/2218 | 106/18723 | 5.23e-04 | 4.52e-03 | 25 |
GO:00439672 | Oral cavity | EOLP | histone H4 acetylation | 18/2218 | 67/18723 | 6.02e-04 | 5.04e-03 | 18 |
GO:004603124 | Oral cavity | EOLP | ADP metabolic process | 22/2218 | 90/18723 | 6.59e-04 | 5.48e-03 | 22 |
GO:00400292 | Oral cavity | EOLP | regulation of gene expression, epigenetic | 24/2218 | 105/18723 | 1.07e-03 | 7.87e-03 | 24 |
GO:00075195 | Oral cavity | EOLP | skeletal muscle tissue development | 32/2218 | 155/18723 | 1.15e-03 | 8.37e-03 | 32 |
GO:000913224 | Oral cavity | EOLP | nucleoside diphosphate metabolic process | 27/2218 | 124/18723 | 1.19e-03 | 8.62e-03 | 27 |
GO:005110124 | Oral cavity | EOLP | regulation of DNA binding | 26/2218 | 118/18723 | 1.21e-03 | 8.75e-03 | 26 |
GO:001908022 | Oral cavity | EOLP | viral gene expression | 22/2218 | 94/18723 | 1.23e-03 | 8.84e-03 | 22 |
GO:000609018 | Oral cavity | EOLP | pyruvate metabolic process | 24/2218 | 106/18723 | 1.24e-03 | 8.90e-03 | 24 |
GO:000647621 | Oral cavity | EOLP | protein deacetylation | 23/2218 | 101/18723 | 1.42e-03 | 9.65e-03 | 23 |
GO:004338817 | Oral cavity | EOLP | positive regulation of DNA binding | 15/2218 | 56/18723 | 1.73e-03 | 1.14e-02 | 15 |
GO:00434709 | Oral cavity | EOLP | regulation of carbohydrate catabolic process | 15/2218 | 56/18723 | 1.73e-03 | 1.14e-02 | 15 |
GO:00075176 | Oral cavity | EOLP | muscle organ development | 57/2218 | 327/18723 | 1.76e-03 | 1.15e-02 | 57 |
GO:00358551 | Oral cavity | EOLP | megakaryocyte development | 7/2218 | 17/18723 | 2.14e-03 | 1.34e-02 | 7 |
GO:004346724 | Oral cavity | EOLP | regulation of generation of precursor metabolites and energy | 27/2218 | 130/18723 | 2.46e-03 | 1.50e-02 | 27 |
GO:00900924 | Oral cavity | EOLP | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 46/2218 | 256/18723 | 2.53e-03 | 1.53e-02 | 46 |
GO:004544415 | Oral cavity | EOLP | fat cell differentiation | 42/2218 | 229/18723 | 2.58e-03 | 1.56e-02 | 42 |
GO:000609125 | Oral cavity | EOLP | generation of precursor metabolites and energy | 79/2218 | 490/18723 | 2.65e-03 | 1.59e-02 | 79 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
EP300 | BAS | Skin | SCCIS | AC104365.1,STX18-AS1,VASN, etc. | 1.89e-01 | |
EP300 | STM | Thyroid | ADJ | AL096865.1,MACF1,DDX17, etc. | 5.60e-01 | |
EP300 | STM | Thyroid | PTC | AL096865.1,MACF1,DDX17, etc. | 4.33e-01 | |
EP300 | CD4TN | Thyroid | ADJ | SECISBP2L,NKRF,SYNE2, etc. | 3.30e-01 | |
EP300 | CD4TN | Thyroid | ATC | SECISBP2L,NKRF,SYNE2, etc. | 1.17e-01 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EP300 | SNV | Missense_Mutation | | c.5528A>C | p.Gln1843Pro | p.Q1843P | Q09472 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
EP300 | SNV | Missense_Mutation | | c.6023N>T | p.Ser2008Phe | p.S2008F | Q09472 | protein_coding | tolerated(0.06) | benign(0.203) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
EP300 | SNV | Missense_Mutation | rs769721803 | c.1349N>T | p.Ala450Val | p.A450V | Q09472 | protein_coding | tolerated(0.07) | possibly_damaging(0.771) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
EP300 | SNV | Missense_Mutation | rs775556373 | c.5854N>G | p.Ile1952Val | p.I1952V | Q09472 | protein_coding | tolerated(0.33) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.4352N>C | p.His1451Pro | p.H1451P | Q09472 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
EP300 | SNV | Missense_Mutation | | c.4608A>T | p.Glu1536Asp | p.E1536D | Q09472 | protein_coding | tolerated(0.07) | probably_damaging(0.994) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
EP300 | SNV | Missense_Mutation | | c.2498N>T | p.Ser833Leu | p.S833L | Q09472 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.992) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.980C>T | p.Ala327Val | p.A327V | Q09472 | protein_coding | tolerated(0.08) | possibly_damaging(0.833) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
EP300 | SNV | Missense_Mutation | novel | c.2744G>T | p.Arg915Leu | p.R915L | Q09472 | protein_coding | tolerated_low_confidence(0.64) | benign(0) | TCGA-E2-A1LK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
EP300 | SNV | Missense_Mutation | novel | c.1440N>A | p.Met480Ile | p.M480I | Q09472 | protein_coding | tolerated(0.54) | benign(0.076) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103579 | CURCUMIN | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103614 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-UNDECYLIDENEMALONATE | CHEMBL1797707 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 187051830 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 249565916 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-PENTADECYLIDENEMALONATE | CHEMBL404916 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103615 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103578 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-DODECYLIDENEMALONATE | CHEMBL1797708 | 21292492 |